Medarex in up to $225M C. diff deal with Merck & Co
Merck & Co and fellow USA-based firm Medarex have licensed an investigational, fully-human monoclonal antibody combination developed to target and neutralize Clostridium difficile toxins A and B from the Massachusetts Biologic Laboratories.
Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1). Medarex and MBL will receive an upfront payment of $60.0 million and are potentially eligible for additional cash payments up to $165.0 million on the achievement of certain milestones associated with the development and approval of a drug candidate, as well as double-digit royalties. All payments will be divided equally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze